Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
anti-Abeta · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| anti-Abeta | DRUG | Intravenous single and multiple doses |
| placebo | DRUG | Intravenous single and multiple doses |
Inclusion Criteria: * Diagnosis of probable AD according to the NINCDS-ADRDA Criteria * Approved AD treatments (AchE inhibitors+/-memantine) must be stable for ≥ 3 months prior to screening * Other prescription medications must be stable for ≥ 1 month prior to screening Exclusion Criteria: * Fema...
Top 20 of 24 competitors
Anti-Abeta is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved for use. The drug is being evaluated for its safety, pharmacokinetics, pharmacodynamics, and immunogenicity in patients with the condition.
Anti-Abeta is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical research to evaluate the drug's potential in treating Alzheimer's Disease.
Anti-Abeta is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety and other characteristics in patients with Alzheimer's Disease, but it is not yet available for clinical use.
Anti-Abeta has been studied in one clinical trial with the identifier NCT00736775. This Phase 1 study, titled "A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease," has been completed. The trial enrolled 56 participants and was randomized and double-blind.
Yes, anti-Abeta is also known as MABT5102A. In the clinical trial NCT00736775, the drug is referred to as anti-Abeta (MABT5102A). This alternative name may be used in scientific literature and regulatory documents, so readers searching for either name will find information about the same investigational drug.